Upadacitinib Shows 1-Year Benefit in Pediatric IBD

(MedPage Today) — LAS VEGAS — Upadacitinib (Rinvoq) showed durable clinical benefit at 1 year among children and adolescents with inflammatory bowel disease (IBD), a single-center study found.
In the retrospective study of 48 patients with…

Source link : https://www.medpagetoday.com/meetingcoverage/ccc/119563

Author :

Publish date : 2026-01-23 21:54:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Upadacitinib Shows 1-Year Benefit in Pediatric IBD

Neonatal Mortality Increased With Number of Mom’s Chronic Conditions

American Psychiatric Association Sues Health Plan Over ‘Ghost Networks’

Related Posts

The Most Honest Health Conversations May Be Those the Law Doesn’t Protect

Bipartisan Bill to Lower Insulin Costs Has Diabetes Advocates Hopeful

Quiz Time: What Drug Was Tied to 8 Deaths?

Dulaglutide or Tirzepatide? Worldwide Biopharma Changes

Beyond the Paywall: The Cost of Lack of Research Access

To Fix a Patient’s Irregular Heartbeat, Doctors First Tested Its Digital ‘Twin’

The Most Honest Health Conversations May Be Those the Law Doesn’t Protect

Bipartisan Bill to Lower Insulin Costs Has Diabetes Advocates Hopeful

Quiz Time: What Drug Was Tied to 8 Deaths?

Dulaglutide or Tirzepatide? Worldwide Biopharma Changes

Beyond the Paywall: The Cost of Lack of Research Access

To Fix a Patient’s Irregular Heartbeat, Doctors First Tested Its Digital ‘Twin’

An Unusual Case of Pneumonia on ‘The Pitt’: An Emergency Doctor Weighs In

Young Adults With Hypertension Have 27% Higher Risk

Categories

Archives